Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator.
Ines C AngererMichael HeckerDirk KoczanLuisa RochJörg FriessAnnelen RügeBrit FitznerNina BoxbergerIna SchröderKristin FlechtnerHans-Jürgen ThiesenAlexander WinkelmannStefanie MeisterUwe K ZettlPublished in: CNS neuroscience & therapeutics (2018)
Our study corroborates changes in the composition of circulating immune cells in response to fingolimod and delineates the respective implications at the RNA level. Our data may be valuable for comparing the effects of novel S1P receptor modulating agents, which may be a therapeutic option for patients with secondary progressive MS as well.
Keyphrases
- multiple sclerosis
- peripheral blood
- end stage renal disease
- white matter
- ejection fraction
- single cell
- chronic kidney disease
- newly diagnosed
- gene expression
- peritoneal dialysis
- signaling pathway
- mass spectrometry
- electronic health record
- dna methylation
- binding protein
- big data
- patient reported outcomes
- deep learning
- machine learning
- data analysis